Y-Biologics, Inc.

Y-Biologics, Inc. is an antibody therapeutics development company engaged in research and development of immuno-oncology and antibody drugs. Its pipeline includes YBL-006, a PD-1 immune-oncology agent in phase 1 clinical trials for solid tumors, along with immunoregulatory monoclonal antibodies such as YBL-011 and AR062, AR166, AR169, and AR170 for solid cancers, and AR153, a pH-dependent antibody for solid cancer. The company was incorporated in 2007 and is headquartered in Daejeon, South Korea.